Side-by-side · Research reference
SelankvsTeriparatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED11/40 cited
BFDA-ApprovedHUMAN-REVIEWED10/62 cited
Selank
Anxiolytic + Cognitive · Russian Pharma
Intranasal · 2–3×/day during stress / cognitive demand
Teriparatide
PTH (1-34) Fragment · FDA-Approved
SQ · Thigh/Abdomen · Once Daily
01Mechanism of Action
Parameter
Selank
Teriparatide
Primary target
Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014
Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026
Pathway
Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007
PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity
Downstream effect
Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007Zaderej 2014
Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites
Feedback intact?
No GABA-receptor binding; no dependence reportedMedvedev 2007
Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption
Origin
Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014
Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH
Antibody development
—
—
02Dosage Protocols
Parameter
Selank
Teriparatide
Frequency
2–3× per day during stress
Once daily
Intermittent administration preserves anabolic effect.
Lower / starter dose
75 mcg / dose
—
Duration
10–14 day cycles, repeated as needed
—
Reconstitution
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
—
Timing
Morning + early afternoon preferred
Morning or evening (flexible)
Half-life
Short (minutes plasma); CNS effect lasts ~3 hr
—
Standard dose (osteoporosis)
—
20 mcg / day
FDA-approved regimen for severe osteoporosis.
Maximum duration
—
24 months lifetime
Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.
Hypoparathyroidism dose
—
20 mcg / day
Used off-label for chronic hypoparathyroidism.
Pelvic fragility fractures
—
20 mcg / day × 8-12 weeks
Accelerates fracture healing; reduces time to union.Crooks 2026
Route
—
Subcutaneous (thigh or abdomen)
Storage
—
Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use
Pharmacogenetics
—
ALDH2 polymorphisms may influence BMD responseObara 2026
ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026
03Metabolic / Fat Loss Evidence
Parameter
Selank
Teriparatide
Fat loss application
—
None — teriparatide is a bone anabolic agent without direct lipolytic activity
04Side Effects & Safety
Parameter
Selank
Teriparatide
Nasal irritation
Mild burning or congestion (transient)
—
Cognitive impairment
None — opposite effect (enhancement)
—
Allergic reaction
Rare hypersensitivity
—
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid — insufficient data
—
Hypercalcemia
—
Transient serum calcium elevation 4-6 hours post-injection
Monitor serum calcium; usually asymptomatic.
Orthostatic hypotension
—
Dizziness, lightheadedness within hours of injection
Nausea
—
Common, usually mild and transient
Leg cramps / Arthralgia
—
Musculoskeletal pain reported in clinical trials
Hypercalciuria
—
Increased urinary calcium excretion; monitor for nephrolithiasis risk
Osteosarcoma (black box warning)
—
Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation
Injection site reaction
—
Erythema, bruising, pain (uncommon)
Absolute Contraindications
Selank
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
Teriparatide
- ·Paget's disease of bone (increased baseline osteosarcoma risk)
- ·Unexplained elevated alkaline phosphatase
- ·Prior skeletal radiation therapy
- ·Skeletal malignancies or bone metastases
- ·Hypercalcemic disorders (primary hyperparathyroidism)
- ·Pregnancy / lactation
Relative Contraindications
Selank
- ·Active autoimmune disease (theoretical via immunomodulation)
Teriparatide
- ·Active or recent nephrolithiasis
- ·Severe renal impairment (CKD G4-G5)
- ·Hypercalciuria without adequate monitoring
05Administration Protocol
Parameter
Selank
Teriparatide
1. Form
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.
2. Administration
Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.
Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.
3. Timing
Morning + early afternoon for cognitive demand; PRN for acute anxiety.
Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.
4. Storage
Refrigerate after reconstitution; ≤30 days. Light-protected.
Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.
5. Caveat
Avoid co-administration with strong sedatives or other anxiolytics initially.
Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.
6. Calcium and vitamin D supplementation
—
Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.